Biologics for severe, chronic plaque psoriasis: An Australian cost-utility analysis

• DOI: 10.1016/j.jdin.2021.06.004
• Publication Date: 2021-08-09T22:46:47Z
• Authors: Helen Y. Sun; Elena Keller; Harish Suresh; Deshan F. Sebaratnam
• Keywords: Ustekinumab

Biologics are a good therapeutic option for severe, chronic plaque psoriasis; however, they come with significant cost to the health care system.To conduct cost-utility analysis of outpatient biologics (adalimumab, etanercept, guselkumab, ixekizumab, risankizumab, secukinumab, tildrakizumab, and ustekinumab) available adults psoriasis from perspective Australian system.A Markov cohort model was constructed estimate quality-adjusted life years (QALYs) costs accrued treatment pathways commencing different first-line biologics, over 96-week time horizon. The adhered Pharmaceutical Benefits Scheme eligibility criteria guidelines.A biologic pathway on tildrakizumab most cost-effective (Australian dollar 39,930; total utility 1.57 QALYs 96 weeks). First-line secukinumab risankizumab had incremental ratios 194,524/QALY 479,834/QALY, respectively, when compared tildrakizumab.The efficacy input parameters were derived international randomized control trials patients United Kingdom, respectively. Findings this study cannot be generalized beyond Australia.Tildrakizumab may considered as adult embarking therapy, economic system.